Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
Retina Foundation of the Southwest
mi
from
Dallas, TX
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
Retina Foundation of the Southwest
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
University of Utah, John A. Moran Eye Center
mi
from
Salt Lake City, UT
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
University of Utah, John A. Moran Eye Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Postoperative Pain Control Following Vitreoretinal Surgery
The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery
Status: Enrolling
Updated:  12/28/2015
Emory University Eye Center
mi
from
Atlanta, GA
Postoperative Pain Control Following Vitreoretinal Surgery
The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery
Status: Enrolling
Updated: 12/28/2015
Emory University Eye Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated:  12/28/2015
Clinical Research Facility
mi
from
Santa Ana, CA
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated: 12/28/2015
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated:  12/28/2015
Clinical Research Facility
mi
from
Chicago, IL
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated: 12/28/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated:  12/28/2015
Clinical Research Facility
mi
from
Ellsworth, ME
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated: 12/28/2015
Clinical Research Facility
mi
from
Ellsworth, ME
Click here to add this to my saved trials
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated:  12/28/2015
Clinical Research Facility
mi
from
Cambridge, MA
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated: 12/28/2015
Clinical Research Facility
mi
from
Cambridge, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated:  12/28/2015
Clinical Research Facility
mi
from
Royal Oak, MI
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated: 12/28/2015
Clinical Research Facility
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated:  12/28/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated: 12/28/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated:  12/28/2015
Clinical Research Facility
mi
from
Fargo, ND
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated: 12/28/2015
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated:  12/28/2015
Clinical Research Facility
mi
from
Houston, TX
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
Status: Enrolling
Updated: 12/28/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Using SightSaver Visual Evoked Potential (VEP) for VEP Monitoring in Prone Spine Surgery
A Pilot Study to Determine the Efficacy and Safety of Detecting Subtle Visual Changes During Visual Evoked Potential (VEP) Monitoring Using SightSaver ™ Flash Visual Evoked Potential Stimulator in Spine Prone Surgery
Status: Enrolling
Updated:  12/28/2015
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Safety and Efficacy of Using SightSaver Visual Evoked Potential (VEP) for VEP Monitoring in Prone Spine Surgery
A Pilot Study to Determine the Efficacy and Safety of Detecting Subtle Visual Changes During Visual Evoked Potential (VEP) Monitoring Using SightSaver ™ Flash Visual Evoked Potential Stimulator in Spine Prone Surgery
Status: Enrolling
Updated: 12/28/2015
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Trial of Rituximab for Graves' Ophthalmopathy
Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy
Status: Enrolling
Updated:  12/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Trial of Rituximab for Graves' Ophthalmopathy
Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy
Status: Enrolling
Updated: 12/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates
Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates
Status: Enrolling
Updated:  12/30/2015
Los Angeles Biomedical Research Institute atHarbor-UCLA Medical Center
mi
from
Torrance, CA
Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates
Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates
Status: Enrolling
Updated: 12/30/2015
Los Angeles Biomedical Research Institute atHarbor-UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief
Status: Enrolling
Updated:  12/30/2015
Clinical Research Facility
mi
from
Azusa, CA
A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief
Status: Enrolling
Updated: 12/30/2015
Clinical Research Facility
mi
from
Azusa, CA
Click here to add this to my saved trials
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/30/2015
Vitreous-Retina-Macula Consultants of New York
mi
from
New York, NY
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/30/2015
Vitreous-Retina-Macula Consultants of New York
mi
from
New York, NY
Click here to add this to my saved trials
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
Phase I Study of Intravitreally Administered Ranibizumab in 20 Subjects With Macular Edema Associated With CRVO.
Status: Enrolling
Updated:  12/31/2015
Vitreous Retina Macula Consultants of New York, P.C.
mi
from
New York City, NY
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
Phase I Study of Intravitreally Administered Ranibizumab in 20 Subjects With Macular Edema Associated With CRVO.
Status: Enrolling
Updated: 12/31/2015
Vitreous Retina Macula Consultants of New York, P.C.
mi
from
New York City, NY
Click here to add this to my saved trials
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Status: Enrolling
Updated:  1/4/2016
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Status: Enrolling
Updated: 1/4/2016
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Click here to add this to my saved trials
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Status: Enrolling
Updated:  1/4/2016
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Status: Enrolling
Updated: 1/4/2016
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Click here to add this to my saved trials
VA Low Vision Intervention Trial
VA Low Vision Intervention Trial
Status: Enrolling
Updated:  1/6/2016
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
VA Low Vision Intervention Trial
VA Low Vision Intervention Trial
Status: Enrolling
Updated: 1/6/2016
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated:  1/7/2016
University of South Alabama, Children's and Women's Hospital
mi
from
Mobile, AL
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated: 1/7/2016
University of South Alabama, Children's and Women's Hospital
mi
from
Mobile, AL
Click here to add this to my saved trials
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated:  1/7/2016
University of California - Irvine Medical Center
mi
from
Irvine, CA
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated: 1/7/2016
University of California - Irvine Medical Center
mi
from
Irvine, CA
Click here to add this to my saved trials
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated:  1/7/2016
Georgia Regents Medical Center
mi
from
Augusta, GA
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated: 1/7/2016
Georgia Regents Medical Center
mi
from
Augusta, GA
Click here to add this to my saved trials
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated:  1/7/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated: 1/7/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated:  1/7/2016
Vidant Medical Center
mi
from
Greenville, NC
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated: 1/7/2016
Vidant Medical Center
mi
from
Greenville, NC
Click here to add this to my saved trials
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated:  1/7/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated: 1/7/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated:  1/7/2016
West Virginia University Hospital
mi
from
Morgantown, WV
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated: 1/7/2016
West Virginia University Hospital
mi
from
Morgantown, WV
Click here to add this to my saved trials
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated:  1/7/2016
University of Wisconsin - Madison
mi
from
Madision, WI
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated: 1/7/2016
University of Wisconsin - Madison
mi
from
Madision, WI
Click here to add this to my saved trials
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated:  1/7/2016
D.A.I. Materno Infantile, S.O.D. Neonatologia e Terapia Intensiva Neonatale - Azienda Ospedaliero-Universitaria Careggi
mi
from
Firenze,
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study
Status: Enrolling
Updated: 1/7/2016
D.A.I. Materno Infantile, S.O.D. Neonatologia e Terapia Intensiva Neonatale - Azienda Ospedaliero-Universitaria Careggi
mi
from
Firenze,
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Ophthalmic Consultants of Connecticut
mi
from
Fairfield, CT
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Ophthalmic Consultants of Connecticut
mi
from
Fairfield, CT
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Bascom Palmer Eye Institute, University of Miami
mi
from
Miami, FL
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Bascom Palmer Eye Institute, University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Stiles Eyecare Excellence and Glaucoma Institute
mi
from
Overland Park, KA
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Stiles Eyecare Excellence and Glaucoma Institute
mi
from
Overland Park, KA
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Vanderbilt Eye Institute
mi
from
Nashville, TN
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Vanderbilt Eye Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Glaucoma Associates of Texas
mi
from
Dallas, TX
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Glaucoma Associates of Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Spokane Eye Clinic
mi
from
Spokane, WA
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Spokane Eye Clinic
mi
from
Spokane, WA
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Vold Vision, PLLC
mi
from
Fayetteville, AR
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Vold Vision, PLLC
mi
from
Fayetteville, AR
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
USC Eye Institute, University of Southern California
mi
from
Los Angeles, CA
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
USC Eye Institute, University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Scripps Clinic
mi
from
San Diego, CA
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Scripps Clinic
mi
from
San Diego, CA
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Minnesota Eye Consultants
mi
from
Bloomington, MN
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Minnesota Eye Consultants
mi
from
Bloomington, MN
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Eye Care Associates & Glaucoma Consultants of Long Island
mi
from
Bethpage, NY
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Eye Care Associates & Glaucoma Consultants of Long Island
mi
from
Bethpage, NY
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
New York Eye & Ear Infirmary
mi
from
New York, NY
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
New York Eye & Ear Infirmary
mi
from
New York, NY
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
Texan Eye
mi
from
Austin, TX
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
Texan Eye
mi
from
Austin, TX
Click here to add this to my saved trials
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated:  1/11/2016
UVA Eye Clinic, University of Virginia
mi
from
Charlottesville, VA
AqueSys Microfistula Implant in Refractory Glaucoma
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma
Status: Enrolling
Updated: 1/11/2016
UVA Eye Clinic, University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Beverly Hills, CA
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Winter Haven, FL
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Boston, MA
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
West Columbia, SC
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
West Columbia, SC
Click here to add this to my saved trials
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Abilene, TX
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Abilene, TX
Click here to add this to my saved trials
Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Pharmacokinetic and Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Status: Enrolling
Updated:  1/14/2016
Call Acucela Clinical Trials Helpdesk for locations
mi
from
Seattle, WA
Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Pharmacokinetic and Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Status: Enrolling
Updated: 1/14/2016
Call Acucela Clinical Trials Helpdesk for locations
mi
from
Seattle, WA
Click here to add this to my saved trials
Clinical Evaluation of Daily Disposable Contact Lenses
Single-Center Clinical Evaluation of Daily Disposable Contact Lenses
Status: Enrolling
Updated:  1/15/2016
University of California, Berkeley Clinical Research Center (UCB-CRC)
mi
from
Berkeley, CA
Clinical Evaluation of Daily Disposable Contact Lenses
Single-Center Clinical Evaluation of Daily Disposable Contact Lenses
Status: Enrolling
Updated: 1/15/2016
University of California, Berkeley Clinical Research Center (UCB-CRC)
mi
from
Berkeley, CA
Click here to add this to my saved trials